Rentschler Biopharma contributed to manufacturing of COVID-19 mRNA vaccine
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
Sorrento announced discovery of salicyn-30 small molecule that strongly inhibits SARS-CoV-2 infection
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
Kindred Biosciences announced expansion of Manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates
On Oct. 7, 2020, Kindred Biosciences announced it had expanded an agreement with Vaxart for the manufacture of…
HHS funded development of needle-free vaccine administration technology
On Oct. 6, 2020, the U.S. Department of Health and Human Services announced funding of a patch that…
BioNTech and Pfizer initiated a rolling submission to EMA for SARS-CoV-2 vaccine candidate BNT162b2
On Oct. 6, 2020, Pfizer and BioNTech announced initiation of a rolling submission to the European Medicines Agency…
Vaxxas announced $22 million award from U.S. Government to advance Vaxxas Needle-Free HD-MAP vaccine patch
On Oct. 5, 2020, Vaxxas announced a $22 million United States government award to support the deployment of…
COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India
On Oct. 2, 2020, AstraZeneca announced the phase I/II clinical trial for the COVID-19 vaccine AZD1222 had resumed…
Amyris delivered sustainable alternative to shark squalene adjuvant enabling vaccines with no sharks killed
On Oct. 1, 2020, Amyris announced that it has begun delivering samples to pharmaceutical companies of a sustainable…
BioNTech and Pfizer announced Nature publication of German phase 1/2 study data from mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 30, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2…
Investigational COVID-19 vaccine well tolerated and generated iImmune response in older adults
On Sept. 29, 2020, the National Institute of Allergy and Infectious Diseases announced that a phase 1 trial…
CureVac Initiated phase 2a clinical trial of COVID-19 vaccine candidate
On Sept. 29, 2020, CureVac announced that the first participant has been dosed in a Phase 2a clinical…
Serum Institute to produce additional 100 million Covid-19 vaccine doses for India and low-and middle-income countries
On Sept. 29, 2020, a further collaboration among the Serum Institute of India (SII), Gavi and the Bill…
New look at COVID-19 cases does not support link between BCG vaccination and lower mortality
On Sept. 29, 2020, In a new Letter, published in PNAS, researchers at La Jolla Institute for Immunology…
Moderna announced publication in The NEJM of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Sept. 29, 2020, Moderna announced the publication of the second interim analysis of the open-label Phase 1…
COVID-19 vaccine generated immune response in older adults
On Sept. 29, 2020, a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection was…
ViroVax licensed adjuvant to be used in India’s first COVID-19 vaccine in human trials
On Sept. 28 2020, ViroVax announced that it had licensed its adjuvant, Alhydroxiquim-II, to Bharat Biotech International, an…
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
Biotechnology | COVID-19 | FDA | Infectious Disease | Life Science News | NIH | Vaccine
INOVIO reported FDA partial clinical hold for planned phase 2/3 trial of COVID-19 vaccine candidate INO-4800
On Sept. 28, 2020, INOVIO announced the U.S. Food and Drug Administration (FDA) had notified the company that…
CDC’s ACIP recommended routine vaccination with a quadrivalent meningococcal conjugate vaccine for adolescents aged 11 or 12 years, with a booster dose at age 16 years.
On Sept. 25, 2020, the Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination with a quadrivalent meningococcal…
Novavax initiated phase 3 efficacy trial of COVID-19 vaccine in the UK
On Sept. 24, 2020, Novavax announced that it had initiated its first Phase 3 study to evaluate the…
Fourth large-scale COVID-19 vaccine trial began in the United States
On Sept. 23, 2020, a fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019…
Sinovacï¾’s Coronavacï¾™, SARS-CoV-2 vaccine, inactivated, announced approval for phase I/II clinical trial in adolescents and children
On Sept. 23, 2020, Sinovac Biotech announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences,…
Johnson & Johnson initiated pivotal global phase 3 clinical trial of Janssen’s COVID-19 vaccine candidate
On Sept. 23, 2020, Johnson & Johnson announced the launch of its large-scale, pivotal, multi-country Phase 3 trial…
Sanofi and GSK signed agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
On Sept. 22, 2020, Sanofi and GSK announced they had signed agreements with the Government of Canada for…
Sinovac commenced phase III clinical trials for COVID-19 vaccine candidate in Turkey
On Sept. 22, 2020, Sinovac Biotech announced that it had recently commenced phase III clinical trials for its…
Serum Institute initiated manufacturing of Codagenix’s intranasal live-attenuated COVID-19 vaccine candidate
On Sept. 22, 2020, Codagenix announced that the Serum Institute of India has begun manufacturing CDX-005, the company’s…
Sanofi and GSK confirmed agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine
On Sept. 18, 2020, Sanofi and GSK finalised and signed an advanced purchase agreement with the European Commission…
BioNTech acquired GMP manufacturing site to expand COVID-19 vaccine production
On Sept. 17, 2020, BioNTech announced an agreement with Novartis to acquire their GMP certified manufacturing facility in…
Atossa Therapeutics received second positive safety assessment in clinical study of AT-301 Coronavirus nasal spray
On Sept. 17, 2020, Atossa Therapeutics announced a positive interim safety assessment from the second cohort of healthy…
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…